Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.71 |
| ▸ | PPARD | Q03181 | 9/20 | 0.64 |
| ▸ | PPARA | Q07869 | 9/20 | 0.64 |
| ▸ | PPARG | P37231 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL4673788 | 0.86 | PPARD (0.67) | FFAR1PPARDPPARAPPARGMEN1 | |
| Bicarbonate SCHEMBL4676328 | 0.84 | PPARD (0.65) | FFAR1PPARDPPARAPPARGMEN1 | |
| SCHEMBL3740273 | 0.83 | FFAR1 (1.00) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3739526 | 0.83 | FFAR1 (1.00) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3739524 | 0.83 | FFAR1 (1.00) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL4674389 | 0.83 | PPARD (0.61) | FFAR1PPARDPPARAPPARGMEN1 | |
| SCHEMBL4674102 | 0.81 | PPARD (0.72) | FFAR1PPARDPPARAPPARGMEN1 | |
| SCHEMBL6235596 | 0.81 | PPARD (0.72) | FFAR1PPARDPPARAPPARGMEN1 | |
| SCHEMBL5859724 | 0.81 | PPARD (0.63) | FFAR1PPARDPPARAPPARGMEN1 | |
| SCHEMBL3519570 | 0.80 | PPARD (0.69) | FFAR1PPARDPPARAPPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | claimed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | claimed |
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | FFAR1 64/4885PPARD 2/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.